12-102855315-C-A
Variant summary
Our verdict is Pathogenic. Variant got 8 ACMG points: 8P and 0B. PS3PM3PP4_Moderate
This summary comes from the ClinGen Evidence Repository: This c.527G>T (p.Arg176Leu) variant in PAH was reported in multiple patients with hyperphenylalaninemia and detected with 11 pathogenic variants (PMID:27121329, 9634518, and 29288420). Experimental studies from two publications have demonstrated this variant to have a deleterious effect (PMID:17924342 and 30037505). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_very-strong, PS3, and PP4_moderate. LINK:https://erepo.genome.network/evrepo/ui/classification/CA114371/MONDO:0009861/006
Frequency
Consequence
NM_000277.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PAH | NM_000277.3 | c.527G>T | p.Arg176Leu | missense_variant | 6/13 | ENST00000553106.6 | NP_000268.1 | |
PAH | NM_001354304.2 | c.527G>T | p.Arg176Leu | missense_variant | 7/14 | NP_001341233.1 | ||
PAH | XM_017019370.2 | c.527G>T | p.Arg176Leu | missense_variant | 6/7 | XP_016874859.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PAH | ENST00000553106.6 | c.527G>T | p.Arg176Leu | missense_variant | 6/13 | 1 | NM_000277.3 | ENSP00000448059 | P1 | |
PAH | ENST00000549111.5 | n.623G>T | non_coding_transcript_exon_variant | 6/6 | 1 | |||||
PAH | ENST00000307000.7 | c.512G>T | p.Arg171Leu | missense_variant | 7/14 | 5 | ENSP00000303500 | |||
PAH | ENST00000551988.5 | n.548G>T | non_coding_transcript_exon_variant | 5/5 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152108Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000518 AC: 13AN: 251160Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135748
GnomAD4 exome AF: 0.0000451 AC: 66AN: 1461804Hom.: 0 Cov.: 34 AF XY: 0.0000468 AC XY: 34AN XY: 727208
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152108Hom.: 0 Cov.: 33 AF XY: 0.0000673 AC XY: 5AN XY: 74290
ClinVar
Submissions by phenotype
Phenylketonuria Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 176 of the PAH protein (p.Arg176Leu). This variant is present in population databases (rs74486803, gnomAD 0.02%). This missense change has been observed in individual(s) with mild phenylketonuria, classical phenylketonuria and hyperphenylalaninemia (PMID: 8088845, 15464430, 17935162, 23500595, 27121329). ClinVar contains an entry for this variant (Variation ID: 631). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PAH protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects PAH function (PMID: 17924342, 27121329). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 14, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Mar 06, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 28, 2024 | - - |
Pathogenic, reviewed by expert panel | curation | ClinGen PAH Variant Curation Expert Panel | Oct 16, 2020 | This c.527G>T (p.Arg176Leu) variant in PAH was reported in multiple patients with hyperphenylalaninemia and detected with 11 pathogenic variants (PMID: 27121329, 9634518, and 29288420). Experimental studies from two publications have demonstrated this variant to have a deleterious effect (PMID: 17924342 and 30037505). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_very-strong, PS3, and PP4_moderate. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jul 26, 2021 | - - |
not provided Pathogenic:3Other:1
not provided, no classification provided | literature only | DeBelle Laboratory for Biochemical Genetics, MUHC/MCH RESEARCH INSTITUTE | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 30, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | May 03, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 18, 2023 | Considered a mild PAH variant as it is associated with significant residual phenylalanine hydroxylase enzyme activity and has been described in association with mild and moderate PKU and hyperphenylalaninemia (PMID: 17935162, 23500595, 8088845); This variant is associated with the following publications: (PMID: 25087612, 23500595, 34828281, 8088845, 26990548, 31623983, 29997390, 10234516, 27121329, 26210745, 30459323, 31589614, 32668217, 33465300, 29288420, 30037505, 17935162) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 27, 2021 | The c.527G>T (p.R176L) alteration is located in exon 6 (coding exon 6) of the PAH gene. This alteration results from a G to T substitution at nucleotide position 527, causing the arginine (R) at amino acid position 176 to be replaced by a leucine (L). Based on data from gnomAD, the T allele has an overall frequency of 0.01% (15/282552) total alleles studied. This alteration has been reported in the compound heterozygous state with a second PAH alteration in several patients with hyperphenylalaninemia and has been reported as a BH4-responsive alteration (Guldberg, 1994; Zurflüh, 2008; Ohlsson, 2017; Aldámiz-Echevarría, 2016). In addition, another alteration at this position (p.R176Q) has also been reported in affected patients (Desviat, 1999; Aldámiz-Echevarría, 2016; Chen, 2018). This amino acid position is not well conserved in available vertebrate species. In vitro functional studies demonstrate reduced residual PAH enzyme activity in multiple cell systems (Gjetting, 2001; Himmelreich, 2018). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. - |
Hyperphenylalaninemia Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 15, 1994 | - - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Aug 16, 2021 | ACMG classification criteria: PS3, PM3, PP4 - |
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 02, 2020 | Variant summary: PAH c.527G>T (p.Arg176Leu) results in a non-conservative amino acid change located in the Aromatic amino acid hydroxylase, C-terminal domain (IPR019774) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.2e-05 in 251160 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in PAH causing Hyperphenylalaninemia (5.2e-05 vs 0.0079), allowing no conclusion about variant significance. c.527G>T has been reported in the literature in multiple individuals affected with Hyperphenylalaninemia (example Aldamiz-Echevarria_2016). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 30%-50% of normal PAH activity (Aldamiz-Echevarria_2016). Multiple clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at